Author: Catherine Thompson
Publication Date: July 2006
Breast cancer is a complex heterogeneous disease characterised by uncontrolled growth and spread of abnormal cells. It is also very prevalent, with reports from the World Health Organization estimating that more than 1.2 million people will be diagnosed with breast cancer in 2005, worldwide. In the United States, breast cancer is the second most common cancer in women (following skin cancer) with 212,930 new cases estimated for 2004 and an associated 40,840 deaths. In Europe, approximately 200,000 women are diagnosed with breast cancer each year (41,000 in the UK). Consequently, breast cancer is a high-priority research area and is recognized as one of the most aggressively pursued diseases in the history of medicine.
Encouragingly, cancer drug therapy is in a time of major transition. This time has been described by Bristol Myers Squibb (New York, NY), as a “golden era,” where decades of cancer research are now being translated into development of next generation therapeutics. Current pharmaceutical pipelines are testimony to the intensity of breast cancer drug development with at least 50 investigational drugs and drug combinations in clinical development.
Breast cancer treatment generally comprises of combinations that include surgery, radiotherapy, hormonal therapy, and chemotherapy. Clinical pipelines now reflect the emergence of two additional new therapy classes, namely, “innovative therapy” and “immunotherapy”. Current treatment is dominated by hormone or endocrine therapy as approximately 70% of breast cancers are hormone-responsive. But early treatments from the new classes are now reaching the market and are set to revolutionise therapy.
非常不错， 支持。 如果能加入目前国内的主要治疗方式以及缺陷就更好了，你说呢？ [标签:content1][标签:content2]
作者:admin@医学,生命科学 2011-08-22 17:22